Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 15/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20339061 | 0.95 | PAICS (0.60) | PAICSPDE3BPDE3AP2RY12 | |
| SCHEMBL20352132 | 0.90 | PAICS (0.59) | PAICSMAPTMAPK1HTT | |
| SCHEMBL20352021 | 0.89 | PAICS (0.48) | PAICSPDE3BPDE3AMAPTMAPK1 | |
| SCHEMBL20352111 | 0.85 | SMN1; SMN2 (0.47) | PAICSMAPTHTTSMN1; SMN2 | |
| SCHEMBL20339071 | 0.85 | PAICS (0.59) | PAICS | |
| SCHEMBL21571629 | 0.85 | PAICS (0.48) | PAICS | |
| SCHEMBL20339037 | 0.84 | PAICS (0.48) | PAICSPDE3BPDE3AMAPTMAPK1 | |
| SCHEMBL20352112 | 0.82 | PAICS (0.49) | PAICS | |
| SCHEMBL24220413 | 0.81 | PAICS (0.44) | PAICSPDE3BPDE3AMAPTMAPK1 | |
| SCHEMBL20352082 | 0.79 | PAICS (0.51) | PAICS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| WO-2018122549-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, CDK12, CDK13 | PAICS 1/4885PDE3B 2893/4885PDE3A 3447/4885 |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, CDK13, CDK12 | PAICS 1/4885PDE3B 2638/4885PDE3A 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.